Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN9A | Q15858 | 3/20 | 0.38 |
| ▸ | ACP1 | P24666 | 1/20 | 0.36 |
| ▸ | F2RL3 | Q96RI0 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | HSD11B1 | P28845 | 7/20 | 0.36 |
| ▸ | KMO | O15229 | 1/20 | 0.35 |
| ▸ | P2RY1 | P47900 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
| ▸ | CTSK | P43235 | 1/20 | 0.34 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1107958 | 0.92 | SCN9A (0.43) | SCN9AACP1F2RL3CYP1A2CYP3A4 | |
| SCHEMBL1107921 | 0.88 | SCN9A (0.45) | SCN9AACP1F2RL3CYP1A2CYP3A4 | |
| SCHEMBL1107918 | 0.87 | SCN9A (0.42) | SCN9AACP1F2RL3HSD11B1KMO | |
| SCHEMBL1107868 | 0.85 | KMO (0.41) | SCN9AF2RL3HSD11B1KMOTRPA1 | |
| SCHEMBL1107908 | 0.85 | KMO (0.44) | SCN9AACP1F2RL3CYP1A2CYP3A4 | |
| SCHEMBL1107947 | 0.83 | KDM4E (0.38) | — | |
| SCHEMBL1107944 | 0.82 | TRPV3 (0.40) | SCN9AP2RY1 | |
| SCHEMBL1107927 | 0.82 | CTSS (0.47) | F2RL3CYP1A2CYP3A4KMOCTSK | |
| SCHEMBL1107893 | 0.82 | HSD11B1 (0.46) | SCN9AACP1F2RL3CYP1A2CYP3A4 | |
| SCHEMBL1107876 | 0.81 | KMT2A (0.44) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8153277-B2 | Compound having thiadiazole ring structure substituted with pyridyl group and organic electroluminescent device | HODOGAYA CHEMICAL CO., LTD. (JP) | 2012-04-10 | — | — | US | disclosed |
| US-8153277-B2 | Compound having thiadiazole ring structure substituted with pyridyl group and organic electroluminescent device | HODOGAYA CHEMICAL CO., LTD. (JP) | 2012-04-10 | — | — | US | disclosed |
| US-20090108750-A1 | COMPOUND HAVING THIADIAZOLE RING STRUCTURE SUBSTITUTED WITH PYRIDYL GROUP AND ORGANIC ELECTROLUMINESCENT DEVICE | HODOGAYA CHEMICAL CO., LTD. (JP) | 2009-04-30 | — | — | US | disclosed |
| US-20090108750-A1 | COMPOUND HAVING THIADIAZOLE RING STRUCTURE SUBSTITUTED WITH PYRIDYL GROUP AND ORGANIC ELECTROLUMINESCENT DEVICE | HODOGAYA CHEMICAL CO., LTD. (JP) | 2009-04-30 | — | — | US | disclosed |
| EP-2009013-A1 | COMPOUND HAVING THIADIAZOLE RING STRUCTURE SUBSTITUTED WITH PYRIDYL GROUP AND ORGANIC ELECTROLUMINESCENT DEVICE | Hodogaya Chemical Co., Ltd. (JP) | 2008-12-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090108750-A1 | COMPOUND HAVING THIADIAZOLE RING STRUCTURE SUBSTITUTED WITH PYRIDYL GROUP AND ORGANIC ELECTROLUMINESCENT DEVICE | OXA1L, SLCO4C1, SLCO2B1 | SCN9A 1892/4885ACP1 3034/4885F2RL3 2710/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.